Vanda Pharmaceuticals Inc.  

(Public, NASDAQ:VNDA)   Watch this stock  
Find more results for Vanda Pharmaceuticals Inc
12.28
-0.02 (-0.16%)
Real-time:   1:46PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 12.12 - 12.39
52 week 5.70 - 19.25
Open 12.31
Vol / Avg. 142,668.00/600,692.00
Mkt cap 416.02M
P/E     -
Div/yield     -
EPS -1.83
Shares 33.88M
Beta 1.81
Inst. own 115%
Nov 5, 2014
Q3 2014 Vanda Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Aug 7, 2014
Q2 2014 Vanda Pharmaceuticals Inc Earnings Call - Webcast
Aug 7, 2014
Q2 2014 Vanda Pharmaceuticals Inc. Earnings Release
Jul 8, 2014
Vanda Pharmaceuticals Inc at Piper Jaffray Catalyst Symposium
Jun 24, 2014
Vanda Pharmaceuticals Inc at JMP Securities Healthcare Conference
Jun 4, 2014
Vanda Pharmaceuticals Inc. at Jefferies Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -198.63% -59.79%
Operating margin -198.91% -60.21%
EBITD margin - -54.53%
Return on average assets -83.55% -14.53%
Return on average equity -791.45% -74.98%
Employees 53 -
CDP Score - -

Address

Suite 300E, 2200 Pennsylvania Ave NW
WASHINGTON, DC 20037
United States - Map
+1-202-7343400 (Phone)
+1-202-2961450 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Vanda Pharmaceuticals Inc. (Vanda) is a biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of central nervous system disorders. The Company�s product portfolio includes tasimelteon, a compound for the treatment of circadian rhythm sleep disorders (CRSD), which is in clinical development for Non-24, Fanapt, a compound for the treatment of schizophrenia, the oral formulation of which is being marketed and sold in the United States by Novartis Pharma AG (Novartis), and VLY-686, a small molecule neurokinin-1 receptor (NK-1R) antagonist.

Officers and directors

Howard H. Pien Independent Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Mihael H. Polymeropoulos M.D. President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
James Patrick Kelly Chief Financial Officer, Senior Vice President, Treasurer, Secretary
Age: 48
Bio & Compensation  - Reuters
Paolo Baroldi M.D., Ph.D. Senior Vice President, Chief Medical Officer
Age: 63
Bio & Compensation  - Reuters
Michael F. Cola Independent Director
Age: 54
Bio & Compensation  - Reuters
Richard W. Dugan Independent Director
Age: 72
Bio & Compensation  - Reuters
Steven K. Galson M.D. Independent Director
Age: 57
Bio & Compensation  - Reuters
Vincent J. Milano Independent Director
Age: 50
Bio & Compensation  - Reuters
H. Thomas Watkins Independent Director
Age: 61
Bio & Compensation  - Reuters